The 12 closest competitors and alternatives to PACIFIC EDGE LIMITED among pharmaceuticals, biotechnology & life sciences companies — ranked by similarity to what PACIFIC EDGE LIMITED actually does, not by market-cap band.
Subscribe to see PACIFIC EDGE LIMITED’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Pacific Edge Ltd is a biotechnology research company headquartered in Dunedin, New Zealand, specializing in genomic diagnostics and the commercialization of the Cxbladder family of tests.
PACIFIC EDGE LIMITED is a pharmaceuticals, biotechnology & life sciences company headquartered in Dunedin, New Zealand. It is publicly listed (PEB) with a market capitalisation of $187.8M. Xcout tracks 4 named people at PACIFIC EDGE LIMITED, including Jon E Bortz (Chairman & Chief Executive Officer).
Ranked by semantic similarity — how close each company is to PACIFIC EDGE LIMITED by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Similar pharmaceuticals, biotechnology & life sciences company
BCAL Diagnostics Limited is a biotechnology firm focused on creating an advanced, non-surgical laboratory blood test for the identification of breast cancer. Its flagship product, the BCAL test, is a lipid biomarker-based blood assay designed for potential use in breast cancer prevention strategies, early screening, and ongoing patient monitoring. This in vitro diagnostic (IVD) technology functions by detecting a unique pattern of lipid biomarkers, which are isolated from extracellular vesicles present in a patient's plasma or blood, thereby enabling the diagnosis of breast cancer cells. Established in 2010, the company's main operations are based in Sydney, Australia.
Similar pharmaceuticals, biotechnology & life sciences company
Proteomics International Laboratories Ltd operates as a medical technology company with a focus on the area of proteomics in Australia, New Zealand, the United States, Europe, India, and Southeast Asia. It provides PromarkerD, a blood test to predict diabetic kidney disease (DKD). The company’s products under development include PromarkerEndo, which has completed clinical validation phase for endometriosis diagnosis; PromarkerEso, which has completed clinical validation trials for esophageal cancer diagnosis; and OxiDx (2-tag), which has completed clinical validation phase for oxidative stress treatment. It is also developing diagnostic tests for that includes DKD - T1D, that is under clinical phase for type 1 diabetes, diabetic retinopathy, and diabetic neuropathy; Asthma and COPD, which has completed proof-of-concept study trials for asthma and chronic obstructive pulmonary disease; Plant Dieback, that is under development phase for phytophthora dieback; Diabetic Retinopathy, which has completed discovery phase for sight-threatening retinopathy; and Diabetic Neuropathy, that is under research phase to investigate predictive biomarkers for diabetic neuropathy. The company also offers analytical services, such as specialist contract research focusing on biomarker discovery, biosimilars quality control, and pharmacokinetic testing for clinical trials. It has strategic collaboration with Harry Perkins Institute of Medical Research, Bioplatforms Australia, The University of Western Australia, Australian Research Council Training Centre, and the Australian Centre. Proteomics International Laboratories Ltd was founded in 2001 and is based in Perth, Australia.
Similar pharmaceuticals, biotechnology & life sciences company
Genetic Technologies Limited (GTG.AX), an Australian molecular diagnostics company founded in Fitzroy in 1987, delivers predictive genetic testing and risk assessment tools. These solutions empower medical professionals in the United States, Canada, Europe, the Middle East, Africa, Latin America, and the Asia Pacific to proactively manage patient health. The company operates through two distinct divisions: EasyDNA and GeneType/Corporate. Among its offerings is BREVAGenplus, a clinically validated test specifically designed for assessing the risk of non-hereditary breast cancer. This product is actively promoted to healthcare providers such as obstetricians/gynecologists, breast surgeons, and specialists in breast health and imaging centers. GTG.AX also provides an array of cancer risk assessment tests, notably GeneType for Colorectal Cancer and GeneType for Breast Cancer, and is currently developing new risk assessments for conditions including ovarian cancer, prostate cancer, coronary artery disease, and type 2 diabetes. In addition to its diagnostic services, the company offers broader genetic testing solutions spanning medical, animal, forensic, and plant applications. Genetic Technologies Limited has established research and collaboration agreements with several prominent institutions, including the University of Melbourne, Translational Genomics Research Institute, and Memorial Sloan Kettering New York Cambridge University.
Similar pharmaceuticals, biotechnology & life sciences company
Genetic Signatures Limited operates as a molecular diagnostics (MDx) enterprise, extending its reach across Australia, the Asia Pacific, the Americas, Europe, the Middle East, Israel, and Africa. The company engineers and manufactures an array of real-time Polymerase Chain Reaction (PCR)-based products, sold under the EasyScreen brand, for the identification of infectious diseases. Moreover, it offers its proprietary MDx 3Base platform technology, enabling hospitals and pathology laboratories to conduct comprehensive screenings for diverse infectious pathogens. Its offerings also encompass detection kits tailored for conditions such as gastrointestinal ailments, respiratory illnesses, sexual health concerns, antimicrobial resistance, meningitis, and tropical diseases. Founded in 2001, the firm is headquartered in Newtown, Australia.
Biotech
Precede Biosciences is a biotechnology company developing blood-based liquid-biopsy technologies for molecular profiling of cancer. Its tests are intended to support oncology research, precision treatment decisions, and pharmaceutical drug-development programs.
Biotechnology
Resolution Bioscience is a precision medicine company specializing in cancer diagnostics, DNA sequencing, and liquid biopsy, located in Bellevue, Washington.
Biotechnology
Predicine Holdings Ltd provides next-generation liquid biopsy platforms and molecular profiling services for cancer research and precision medicine. The company utilizes proprietary blood- and urine-based assays to analyze circulating tumor DNA and RNA, serving biopharmaceutical partners and clinical researchers in oncology drug development and clinical trials.
Biotechnology
ExosomeDx (Exosome Diagnostics) develops noninvasive liquid-biopsy diagnostics based on RNA carried in exosomes, including the ExoDx Prostate test for assessing prostate-cancer risk. Its products serve urologists, oncologists, laboratories, and patients by supporting clinical decision-making without relying solely on invasive biopsy.
Biotech
Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It also provides the nCounter analysis system services. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
Biotechnology
EcoGenome LLC is a biotechnology company that develops diagnostic tests and kits for cancer, specifically focusing on prostate cancer. The company identifies individual tumor genetic vulnerabilities to help inform precise therapy planning and treatment choices for patients.
Healthcare
Genomic Diagnostics is an Australian provider of genetic testing services, including prenatal, oncology, and pharmacogenomic screening, operating as part of the Healius Pathology network.
Biotech
Exact Sciences Corporation is an American molecular diagnostics company based in Madison, Wisconsin, specializing in the detection of early-stage cancers. The company provides products for the detection and prevention of colorectal cancer, including Cologuard, the first stool DNA test for colorectal cancer, along with additional screening and precision oncological tests for other types of cancer.
Search any company we track to see its competitive set.
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
Funding, investors, tech stack, hiring signals, leadership and corporate events — for PACIFIC EDGE LIMITEDand every competitor above — in one live dashboard.
Subscribe to Xcout Intel →